Testicular germ cell tumor: Short and long-term side effects of treatment among survivors

Gil,Thierry; Sideris,Spyridon; Aoun,Fouad; van Velthoven,Roland; Sirtaine,Nicolas; Paesmans,Marianne; Ameye,Lieveke; Awada,Ahmad; Devriendt,Daniel; Peltier,Alexandre

doi:10.3892/mco.2016.960

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors

Authors:
- Thierry Gil
- Spyridon Sideris
- Fouad Aoun
- Roland van Velthoven
- Nicolas Sirtaine
- Marianne Paesmans
- Lieveke Ameye
- Ahmad Awada
- Daniel Devriendt
- Alexandre Peltier
View Affiliations

Affiliations: Department of Oncology, Jules Bordet Institute, University ULB of Brussels, B‑1000 Brussels, Belgium, Department of Urology, Jules Bordet Institute, University ULB of Brussels, B‑1000 Brussels, Belgium, Department of Pathology, Jules Bordet Institute, University ULB of Brussels, B‑1000 Brussels, Belgium, Department of Biostatistics, Data Center, Jules Bordet Institute, University ULB of Brussels, B‑1000 Brussels, Belgium
Published online on: July 14, 2016 https://doi.org/10.3892/mco.2016.960
Pages: 258-264

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long-term prognosis of germ cell tumor (GCT) types is excellent, however, treatment is associated with non-negligible complication rates and a negative impact on quality of life. The present study described treatment results in terms of survival, both short and long‑term toxicity, and paternity rates in a cohort of patients treated at Jules Bordet Institute, University ULB of Brussels (Brussels, Belgium). The present study analyzed the data of a cohort of patients with GCT types. Pre‑operative patient and tumor characteristics were described. Performance status, pulmonary function tests and renal clearance prior to chemotherapy were noted. Chemotherapeutic regimens and their associated toxicities were analyzed. The duration to event‑free, cancer‑specific and overall survivals were estimated using Kaplan‑Meier curves. A total of 115 patients (median age, 31-years-old) were treated for a GCT at Jules Bordet Institute. At a median follow‑up of 6‑years, 11 (10%) patients had relapsed and 2 (2%) developed a second malignant neoplasm. At the final follow‑up, 97 (89%) and 6 (5.5%) patients exhibited complete and partial remission, respectively. A total of 6% of patients exhibited a progressive disease. In terms of short‑term toxicity, 11% of patients presented with febrile neutropenia. The 10‑year overall survival rate and relapse‑free survival rate were 93.4 and 89.8%, respectively. The paternity rate post‑treatment was 27%. Testicular GCT survivors suffered from short‑ and long-term treatment-associated side effects on both a physical and psychological level. A long‑term close follow‑up is necessary in order to assist the patient with these treatment-induced complications.

View Figures

View References

1	Sui W, Morrow DC, Bermejo CE and Hellenthal NJ: Trends in testicular cancer survival: A large population-based analysis. Urology. 85:1394–1398. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M and Møller H: Trends in testicular cancer incidence and mortality in 22 European countries: Continuing increases in incidence and declines in mortality. Int J Cancer. 118:3099–3111. 2006. View Article : Google Scholar : PubMed/NCBI
3	La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P and Levi F: Cancer mortality in Europe, 2000–2004 and an overview of trends since 1995. Ann Oncol. 21:1323–1360. 2010. View Article : Google Scholar : PubMed/NCBI
4	Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E and Berrino F: RARECARE Working Group: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. Eur J Cancer. 48:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sender L and Zabokrtsky KB: Adolescent and young adult patients with cancer: A milieu of unique features. Nat Rev Clin Oncol. 12:465–480. 2015. View Article : Google Scholar : PubMed/NCBI
6	Petersen PM, Skakkebaek NE and Giwercman A: Gonadal function in men with testicular cancer: Biological and clinical aspects. APMIS. 106:24–34. 1998. View Article : Google Scholar : PubMed/NCBI
7	Tomlinson M, Meadows J, Kohut T, Haoula Z, Naeem A, Pooley K and Deb S: Review and follow-up of patients using a regional sperm cryopreservation service: Ensuring that resources are targeted to those patients most in need. Andrology. 3:709–716. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ng AK, Kenney LB, Gilbert ES and Travis LB: Secondary malignancies across the age spectrum. Semin Radiat Oncol. 20:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
9	Howard R, Gilbert E, Lynch CF, Hall P, Storm H, Holowaty E, Pukkala E, Langmark F, Kaijser M, Andersson M, et al: Risk of leukemia among survivors of testicular cancer: A population-based study of 42,722 patients. Ann Epidemiol. 18:416–421. 2008. View Article : Google Scholar : PubMed/NCBI
10	Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst. 102:1114–1130. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lackner JE, Märk I, Schatzl G, Marberger M and Kratzik C: Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Urology. 69:754–758. 2007. View Article : Google Scholar : PubMed/NCBI
12	Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J and Dearnaley DP: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 21:1513–1523. 2003. View Article : Google Scholar : PubMed/NCBI
13	Malec JF, Romsaas EP, Messing EM, Cummings KC and Trump DL: Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies. J Clin Psychol. 46:551–557. 1990. View Article : Google Scholar : PubMed/NCBI
14	Fleer J, Hoekstra HJ, Sleijfer DT and Hoekstra-Weebers JE: Quality of life of survivors of testicular germ cell cancer: A review of the literature. Support Care Cancer. 12:476–486. 2004. View Article : Google Scholar : PubMed/NCBI
15	Huddart RA and Kataja VV: ESMO Guidelines Task Force: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of testicular seminoma. Ann Oncol. 16(Suppl 1): i40–i42. 2005. View Article : Google Scholar : PubMed/NCBI
16	Huddart RA and Purkalne G: ESMO Guidelines Task Force: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Ann Oncol. 16(Suppl 1): i37–i39. 2005. View Article : Google Scholar : PubMed/NCBI
17	International germ cell consensus classification: A prognostic factor based staging system for metastatic germ-cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 15:594–603. 1997.PubMed/NCBI
18	Dieckmann KP and Pilchlmeier U: Clinical epidemiology of testicular germ cell tumors. World J Urol. 22:2–14. 2004. View Article : Google Scholar : PubMed/NCBI
19	Greene MH, Kratz CP, Mai PL, Mueller C, Peters JA, Bratslavsky G, Ling A, Choyke PM, Premkumar A, Bracci J, et al: Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer. 17:R109–R121. 2010. View Article : Google Scholar : PubMed/NCBI
20	Srivastava A and Kreiger N: Cigarette smoking and testicular cancer. Cancer Epidemiol Biomarkers Prev. 13:49–54. 2004. View Article : Google Scholar : PubMed/NCBI
21	Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL and Basen-Engquist KM: Testis cancer survivors' health behaviors: Comparison with age-matched relative and demographically matched population controls. J Clin Oncol. 28:2274–2279. 2010. View Article : Google Scholar : PubMed/NCBI
22	Abern MR, Dude AM and Coogan CL: Marital status independently predicts testis cancer survival-an analysis of the SEER database. Urol Oncol. 30:487–493. 2012. View Article : Google Scholar : PubMed/NCBI
23	Bokemever C, kuczyk MA, Köhne H, Einsele H, Kynast B and Schmoll HJ: Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol. 72:1–9. 1996. View Article : Google Scholar
24	Damjanov I and Wewer-Albrechtsen N: Testicular germ cell tumors and related research from a historical point of view. Int J Dev Biol. 57:197–200. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). International Agency for Research on Cancer (Lyon, France). 2010.http://globocan.iarc.frAccessed. December 12–2014PubMed/NCBI
26	Shanmugalingam T, Soultati A, Chowdhury S, Rudman S and Van Hemelrijck M: Global incidence and outcome of testicular cancer. Clin Epidemiol. 5:417–427. 2013.PubMed/NCBI
27	Reilley MJ, Jacobs LA, Vaughn DJ and Palmer SC: Health behaviors among testicular cancer survivors. J Community Support Oncol. 12:121–128. 2014.PubMed/NCBI
28	Fosså SD, Dahl AA and Loge JH: Fatigue, anxiety and depression in long-term survivors of testicular cancer. J Clin Oncol. 21:1249–1254. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hotaling JM, Patel DP, Vendryes C, Lopushnyan NA, Presson AP, Zhang C, Muller CH and Walsh TJ: Predictors of sperm recovery after cryopreservation in testicular cancer. Asian J Androl. 18:35–38. 2016. View Article : Google Scholar : PubMed/NCBI
30	Magelssen H, Brydøy M and Fosså SD: The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol. 3:312–322. 2006. View Article : Google Scholar : PubMed/NCBI
31	Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T and Dahl O: Paternity following treatment for testicular cancer. Nat Cancer Inst. 97:1580–1588. 2005. View Article : Google Scholar
32	Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Weiderpass E, Tracey E, Brewster DH, McBride ML, et al: Second malignancies among survivors of germ-cell testicular cancer: A pooled analysis between 13 cancer registries. Int J Cancer. 120:623–631. 2007. View Article : Google Scholar : PubMed/NCBI